Company profile
Petlife Pharmaceuticals, Inc.
OTC: PTLF · Healthcare · Drug Manufacturers - Specialty & Generic
#1161 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 29
v0.1 · 5/100 weight · pillars only
↑ listing tenure, disclosure history · ↓ workforce scale, return on assets
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$23.3M
Employees
1
as of 2026-08-28
Market cap
$19.7k
as of 2026-08-28
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02017
Net income-$23.3M-$23.3M2017
Operating income-$22.7M-$22.7M2017
Total assets$55.0k$55.0k2017
Liabilities$1.4M$1.4M2017
Equity-$1.4M-$1.4M2017
Revenue trend
FY2010 – FY2017 · USD
FY10
FY11
FY12
FY13
FY14
FY15
FY16
FY17
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Petlife Pharmaceuticals, Inc.’s revenue?
Petlife Pharmaceuticals, Inc. booked $0 in FY2017 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Spencer Pharmaceutical Inc.——Pazoo, Inc.——THC Therapeutics, Inc.——Healthcare Solutions Management Group, Inc.——Stem Cell Authority, Ltd.——Scopus BioPharma Inc.——Neighbors
Los Angeles →Key facts
CEOSebastian Serrell-Watts
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersLos Angeles, CA
ExchangeOTC: PTLF
Employees1
IPO date2008-05-14
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.